8-K: Venus Concept to Delist from Nasdaq, Extends Loan Terms

Venus Concept Inc. announced its voluntary delisting from Nasdaq and deregistration with the SEC, alongside securing short-term waivers for loan liquidity requirements and a brief extension of its bridge loan maturity date.

Summary

• Venus Concept Inc. (VERO) entered into a Consent Agreement with Madryn Health Partners, LP and Madryn Health Partners (Cayman Master), LP on January 14, 2026.
• This agreement waived certain minimum liquidity requirements under the Main Street Priority Loan Agreement through January 31, 2026.
• The company also executed the Twenty Fourth Bridge Loan Amendment on January 14, 2026, extending the Bridge Loan's maturity date from January 14, 2026, to January 31, 2026.
• The Bridge Loan amendment also waived certain minimum liquidity requirements through January 31, 2026.
• On January 20, 2026, the Board of Directors approved a plan to voluntarily delist the company's common stock from the Nasdaq Capital Market and deregister with the SEC.
• The decision was based on high costs, low trading volumes, and regulatory burdens associated with being a public company, aiming to reallocate resources to enhance long-term stockholder value and achieve meaningful annual savings.
• The company intends to file Form 25 around January 30, 2026, with Nasdaq trading expected to cease around February 6, 2026.
• A Form 15 filing is planned around February 9, 2026, to suspend SEC reporting obligations.

Sentiment

Score: 2

Explanation: The voluntary delisting from Nasdaq, deregistration with the SEC, and the need for repeated loan amendments and liquidity waivers point to significant financial distress and a retreat from public markets. While management cites cost savings and a focus on long-term value, these actions are generally viewed negatively by investors due to reduced transparency and liquidity.

Positives

• Anticipated meaningful annual savings from delisting and deregistration.
• Ability to reallocate resources to enhance long-term stockholder value.
• Waiver of minimum liquidity requirements under both the MSLP Loan Agreement and the Bridge Loan until January 31, 2026, providing short-term financial flexibility.
• Extension of the Bridge Loan maturity date to January 31, 2026, avoiding immediate default.

Negatives

• Voluntary delisting from Nasdaq, indicating a retreat from public markets.
• Deregistration with the SEC, leading to a suspension of periodic reporting obligations, reducing transparency for investors.
• Repeated amendments to loan agreements (this is the "Twenty Fourth Bridge Loan Amendment"), suggesting ongoing financial distress or difficulty meeting terms.
• Waivers of minimum liquidity requirements imply the company is struggling to maintain sufficient cash reserves.
• The short duration of the waivers and extensions (until January 31, 2026) suggests a very near-term financial crunch.

Risks

• Loss of liquidity for shareholders due to delisting from Nasdaq.
• Reduced transparency and availability of financial information for investors after deregistration.
• Potential for further financial difficulties given the need for repeated loan amendments and liquidity waivers.
• Uncertainty regarding the company's ability to execute its turnaround plan and achieve long-term financial stability outside of public markets.
• Forward-looking statements may turn out to be inaccurate due to known and unknown risks, uncertainties, and other factors beyond the company's control.

Future Outlook

The company anticipates realizing meaningful annual savings from delisting and deregistering its common stock. Management believes this action will help facilitate the company's ability to continue executing its turnaround plan and position it for sustained, long-term financial success in collaboration with Madryn Asset Management. The timing of the delisting and termination of SEC reporting obligations is also outlined.

Management Comments

• "The Board of Directors, after thorough evaluation, has determined this action is in the best interests of the Company and its shareholders. We believe the reduced costs for compliance will help facilitate the Company's ability to continue to execute our turnaround plan." Rajiv De Silva, Chief Executive Officer.
• "Venus will continue to work together with Madryn Asset Management to position Venus for sustained, long-term financial success." Rajiv De Silva, Chief Executive Officer.

Industry Context

The medical aesthetic technology industry is competitive and often requires significant R&D and marketing investments. Companies in this sector typically benefit from public market access for capital and visibility. Venus Concept's decision to delist suggests it is facing challenges that make public market participation unsustainable or less beneficial, potentially indicating a struggle to compete effectively or achieve profitability in its current structure. This move could be seen as a strategic retreat to focus on private restructuring or a niche market, contrasting with industry trends where companies often seek public listings for growth capital.

Comparison to Industry Standards

• NA. The filing does not provide performance metrics or specific project results to compare against industry benchmarks or comparable companies. The delisting itself is a deviation from the standard path of publicly traded companies, often indicating underperformance relative to public market expectations.

Corporate Governance

Stakeholder Impact

• Shareholders: Will lose the ability to trade shares on Nasdaq, significantly reducing liquidity and transparency. The value of their investment will become harder to ascertain and realize.
• Creditors (Madryn): Have agreed to short-term waivers and extensions, indicating a willingness to work with the company but also highlighting the company's financial precariousness. Their position is secured by the loan agreements.
• Employees: The company's focus on cost savings and a turnaround plan could imply potential operational changes, though no direct impact on employees is stated.
• Customers/Suppliers: No direct impact mentioned, but a company undergoing such significant restructuring might face questions about long-term stability.

Next Steps

• File Form 25 with the SEC on or about January 30, 2026, to effect voluntary withdrawal of listing from Nasdaq.
• Trading on Nasdaq will cease on or about February 6, 2026.
• File Form 15 with the SEC on or about February 9, 2026, to suspend reporting obligations under Section 15(d) of the Exchange Act.
• Continue to work with Madryn Asset Management to position the company for sustained, long-term financial success.
• Implement the turnaround plan, leveraging anticipated cost savings from delisting and deregistration.

Key Dates

Recommendation

The voluntary delisting from Nasdaq and deregistration with the SEC, coupled with the need for repeated loan amendments and very short-term liquidity waivers, are strong indicators of severe financial distress and a fundamental shift away from public market transparency. For existing shareholders, this means a significant loss of liquidity, reduced access to information, and increased difficulty in valuing or selling their shares. The company's stated reasons of cost savings and focusing on long-term value, while understandable from a private company perspective, represent a significant negative for public investors. The stock is highly likely to become illiquid and its value will be extremely difficult to determine.

Keywords

Venus Concept, VERO, Nasdaq delisting, SEC deregistration, loan amendment, liquidity waiver, Madryn Health Partners, medical aesthetic technology, corporate governance, financial distress